Press Releases
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
-
May 9, 2024
EsophaCap device recalled due to recent publication of serious device failures Lucid Diagnostics' EsoCheck® unaffected by recall and remains the gold standard for non-endoscopic cell collection...
-
May 7, 2024
Final closing yields total gross proceeds of $29.8 million from offering Mr. Matheis serves as President and CEO of Sentara Health, one of the largest not-for-profit integrated health systems in...
-
May 3, 2024
PAVmed Inc. (Nasdaq: PAVM, PAVMZ) ("PAVmed" or the "Company"), a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, and digital health sectors,...
-
May 2, 2024
Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company and majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM,...
-
May 2, 2024
EsoGuard demonstrated unprecedented early precancer detection, including 89% sensitivity at detecting short segment early precancer, the primary target of esophageal precancer testing Publication...
-
Apr 30, 2024
PAVmed Inc. (Nasdaq: PAVM) ("PAVmed" or the "Company") a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, and digital health sectors, and its...
-
Apr 8, 2024
Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company, and majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM,...
-
Mar 26, 2024
Lucid's quarterly revenue increased 33 percent sequentially Launched wholly-owned incubator, PMX, to complete development and commercialization of existing portfolio technologies Conference call...
-
Mar 25, 2024
Quarterly EsoGuard® revenue increased 33 percent sequentially Expanding EsoGuard clinical validity and clinical utility data poised to drive medical policy coverage, including line of sight to...
-
Mar 21, 2024
Prospective VA screening study demonstrates excellent EsoGuard sensitivity of 92.9% and negative predictive value of 98.6% compared to upper gastrointestinal endoscopy Authors conclude that...
-
Mar 21, 2024
The incubator, PMX, and medical device firm Hatch Medical, execute joint venture agreement to complete their development and commercialization, starting with PortIO NEW YORK, March 21, 2024...
-
Mar 20, 2024
Lucid and collaborators will present data on three studies on EsoGuard® esophageal precancer testing and one on a new genetic classifier of esophageal neoplasia NEW YORK, March 20, 2024...
-
Mar 13, 2024
PAVmed Inc. (Nasdaq: PAVM, PAVMZ) ("PAVmed" or the "Company"), a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, and digital health sectors,...
-
Mar 12, 2024
Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company and majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM,...
-
Feb 16, 2024
Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company, and majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM,...
-
Feb 15, 2024
Contrasts EsoCheck's powerful cell collection capabilities to "cruder, decades-old" technologies during comments on patient access to medical technology innovation NEW YORK, Feb. 15, 2024...
-
Feb 8, 2024
The World Trade Center Health Program will now cover the cost of EsoGuard testing for its more than 120,000 participants NEW YORK, Feb. 8, 2024 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("
-
Dec 12, 2023
Studies demonstrate real-world clinical utility of EsoGuard testing to detect esophageal precancer NEW YORK, Dec. 12, 2023 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the...
-
Dec 11, 2023
PAVmed shareholders as of January 15, 2024 will participate in distribution of approximately 3.3 million shares of Lucid common stock NEW YORK, Dec. 11, 2023 /PRNewswire/ -- PAVmed Inc. (Nasdaq:...
-
Dec 4, 2023
PAVmed shareholders as of January 15, 2024 will participate in distribution of approximately 3.3 million shares of Lucid common stock 1-for-15 reverse stock split to be effective as of market open on
-
Nov 16, 2023
Industry veterans join executive team as VP, Market Access and VP, Employer Markets Shaun M. O'Neil promoted to Lucid's President and COO NEW YORK, Nov. 16, 2023 /PRNewswire/ -- Lucid Diagnostics Inc.
-
Nov 14, 2023
Lucid's quarterly revenue increased 392 percent sequentially Veris Health commercial expansion efforts underway, with next-generation Veris Cancer Care Platform launching in Q4 Conference call and...
-
Nov 13, 2023
Quarterly EsoGuard® test volume and revenue increased 17 percent and 392 percent sequentially, respectively Conference call and webcast to be held tomorrow, November 14th at 8:30 AM EST NEW YORK,...
-
Nov 9, 2023
EsoGuard 2.0 incorporates advanced molecular techniques and leverages improvements in sample DNA yields and processes to enhance assay performance and lower costs Lucid Diagnostics Investor Day,...
-
Nov 2, 2023
Lishan Aklog, M.D., Chairman & CEO, to Present November 16, 2023, in New York NEW YORK, Nov. 2, 2023 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company") a...
-
Nov 1, 2023
PAVmed Inc. (Nasdaq: PAVM, PAVMZ) ("PAVmed" or the "Company"), a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, and digital health sectors,...
-
Oct 31, 2023
Clinical registries are collecting real-world clinical utility and clinical validity data on EsoGuard testing in general at-risk populations and firefighters, respectively Initial combined...
-
Oct 31, 2023
Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company and majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM,...
-
Sep 21, 2023
PAVmed Inc. (Nasdaq: PAVM, PAVMZ) ("PAVmed"), a diversified commercial-stage medical technology company operating in the medical device, diagnostics, and digital health sectors, and its...
-
Sep 21, 2023
PAVmed Inc. (Nasdaq: PAVM, PAVMZ) ("PAVmed"), a diversified commercial-stage medical technology company operating in the medical device, diagnostics, and digital health sectors, and its...
-
Sep 7, 2023
Multicenter observational study documents excellent concordance of EsoGuard results with subsequent medical decision-making by multiple physicians NEW YORK, Sept. 7, 2023 /PRNewswire/ -- Lucid...
-
Sep 6, 2023
Study documents 100 percent concordance between EsoGuard® test results and subsequent medical decision-making Timely results support recently proposed federal legislation which seeks to fund...
-
Aug 24, 2023
EsoGuard Testing now incorporated in Texas-based Ancira Auto Group's corporate Health and Wellness Program NEW YORK, Aug. 24, 2023 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or...
-
Aug 15, 2023
EsoGuard® test volume continues to grow as Lucid makes strides with commercial expansion and additional supporting data Veris Health prepares to launch the next generation of the Veris Cancer...
-
Aug 14, 2023
Quarterly EsoGuard® test volume increased 20 percent sequentially and 159 percent annually Revenue cycle management upgrade completed with immediate positive impact to claims processing and payments
-
Jul 31, 2023
PAVmed Inc. (Nasdaq: PAVM, PAVMZ) ("PAVmed" or the "Company"), a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, and digital health sectors,...
-
Jul 31, 2023
Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company and majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM,...
-
Jul 26, 2023
Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid Diagnostics" or "Lucid"), a commercial-stage cancer prevention diagnostics company and a majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM,...
-
Jul 19, 2023
Advocated stronger transparency and predictability, and inclusion of diagnostics, in federal proposals to improve equitable access to innovative lifesaving technologies Highlighted EsoGuard's...
-
Jun 28, 2023
PAVmed Inc. (NASDAQ: PAVM, PAVMZ) ("PAVmed" or the "Company"), a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, and digital health sectors,...
-
Jun 14, 2023
Dr. Lishan Aklog, PAVmed CEO, to participate in Fireside Chat with Maxim's Anthony Vendetti on Wednesday, June 21, 2023, at 1:30 PM ET. NEW YORK, June 14, 2023 /PRNewswire/ -- PAVmed Inc. (NASDAQ:...
-
Jun 5, 2023First esophageal precancer detection event utilizing an EsoGuard mobile test unit to be hosted today by Florida Digestive Health Specialists in Sarasota, Florida
Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid Diagnostics" or "Lucid"), a commercial-stage cancer prevention diagnostics company and a majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM,...
-
Jun 2, 2023
PAVmed Inc. (Nasdaq: PAVM, PAVMZ) ("PAVmed"), a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, and digital health sectors, and its...
-
Jun 1, 2023
EsoGuard® continues to demonstrate excellent esophageal precancer and cancer detection performance, including in most prevalent and challenging precancer subgroup—short segment non-dysplastic...
-
May 16, 2023
EsoGuard® test volume gains momentum as Lucid expands high-volume testing events PAVmed appoints President for Veris Health and expands commercial footprint Conference call and webcast to be held...
-
May 15, 2023
EsoGuard® test volume increases 57 percent sequentially and 245 percent year-on-year Conference call and webcast to be held tomorrow, May 16th at 8:30 AM EST NEW YORK, May 15, 2023 /PRNewswire/...
-
May 11, 2023EsoGuard® continues to demonstrate excellent esophageal precancer and cancer detection performance, including in most prevalent and challenging precancer subgroup—short segment non-dysplastic Barrett's Esophagus
Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company, and majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM,...
-
May 5, 2023Conference Call and Webcast at 8:30AM Eastern Time
Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company and majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM,...
-
May 5, 2023Conference Call and Webcast at 8:30AM Eastern Time
PAVmed Inc. (Nasdaq: PAVM, PAVMZ) ("PAVmed" or the "Company"), a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, and digital health sectors,...
-
Apr 25, 2023Manning Brings Vast Digital Health Experience Focused on Demonstrable Growth and Commercial Excellence
PAVmed Inc. (Nasdaq: PAVM, PAVMZ) ("PAVmed"), a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, and digital health sectors, and its...